Skip to content

EBITDA at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$78.09M+6.7%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$102.98M-38.6%
CG Oncology logo
CG OncologyCGON
-$65.55M-55.4%
Eli Lilly logo
Eli LillyLLY
Gilead Sciences logo
Gilead SciencesGILD
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Calculated from Celcuity’s reported figures.

$50.5Mebit+
$47.0KDepreciation Depletion & Amortization
=-$50.46M

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's EBITDA?
Celcuity (CELC) reported EBITDA of -$50.46M in Q1 2026.
How has Celcuity's EBITDA changed year-over-year?
Celcuity's EBITDA decreased by 39.8% year-over-year, from -$36.1M to -$50.46M.
What is the long-term trend for Celcuity's EBITDA?
Over 4 years (2021 to 2025), Celcuity's EBITDA has grown at a 57.4% compound annual growth rate (CAGR), from -$28.05M to -$172.03M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.